Serum IL-2 and soluble IL-2 receptor concentrations after treatment with daclizumab
| Study Day . | IL-2 . | sIL-2R . | ||
|---|---|---|---|---|
| n . | pg/mL (range) . | n . | pg/mL (range) . | |
| 1 | 25 | 189 (21-1478) | 25 | 3095 (106-10 330) |
| 8 | 26 | 109 (11-1336) | 26 | 188 (37-2452) |
| 15 | 25 | 119 (14-1229) | 25 | 243 (51-1635) |
| 22 | — | — | 21 | 172 (42-1200) |
| 29 | — | — | 20 | 171 (53-738) |
| 36 | — | — | 20 | 185 (50-1920) |
| 43 | — | — | 12 | 307 (86-875) |
| 60 | — | — | 17 | 1432 (124-17 177) |
| 90 | — | — | 12 | 4668 (243-10 312) |
| Study Day . | IL-2 . | sIL-2R . | ||
|---|---|---|---|---|
| n . | pg/mL (range) . | n . | pg/mL (range) . | |
| 1 | 25 | 189 (21-1478) | 25 | 3095 (106-10 330) |
| 8 | 26 | 109 (11-1336) | 26 | 188 (37-2452) |
| 15 | 25 | 119 (14-1229) | 25 | 243 (51-1635) |
| 22 | — | — | 21 | 172 (42-1200) |
| 29 | — | — | 20 | 171 (53-738) |
| 36 | — | — | 20 | 185 (50-1920) |
| 43 | — | — | 12 | 307 (86-875) |
| 60 | — | — | 17 | 1432 (124-17 177) |
| 90 | — | — | 12 | 4668 (243-10 312) |
—, not done.